Sarah Boyce, Avidity Biosciences CEO
August 9, 2024 10:52 AM EDT
R&D

Avid­i­ty CEO says it's ‘full steam ahead’ in DMD as stock ral­lies on Phase 1/2 win

Andrew Dunn

Senior Biopharma Correspondent

The Duchenne mus­cu­lar dy­s­tro­phy com­mu­ni­ty re­ceived some rare good news on Fri­day when Avid­i­ty Bio­sciences re­port­ed sur­pris­ing­ly pos­i­tive clin­i­cal re­sults in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times